

Rev. 11/98



RECEIVED

AUG 8 2000

Docket No. STK-6

1614

PTTS

TECH CENTER 1600/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned

RECEIVED

Group Art Unit : 1614

AUG 07 2000

Applicants : Ugo Ripamonti, et al.

TECH CENTER 1600/2000

Serial No. : 09/540,466

Filed : March 31, 2000

For : METHODS FOR INDUCING ANGIOGENESIS
USING MORPHOGENIC PROTEINS AND
STIMULATORY FACTORS

New York, New York
July 28, 2000

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

[] within three months of the application filing date;

[X] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.98, submission of this Statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

Karen Mangasarian

James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Karen Mangasarian (Reg. No. 43,772)
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

I **Hereby Certify** that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on

Claire J. Mancini
Signature of Person Signing



STK-6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1614
Applicants : Ugo Ripamonti, et al.
Serial No. : 09/540,466
Filed : March 31, 2000
For : METHODS FOR INDUCING ANGIOGENESIS
USING MORPHOGENIC PROTEINS AND
STIMULATORY FACTORS

New York, New York
July 28, 2000

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorney, make of record the documents listed below (copies enclosed herewith). A completed Form PTO-1449 listing all of the documents is enclosed herewith.

Applicants respectfully request that the documents listed below be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

United States Patents

<u>Inventor</u>	<u>Serial No.</u>	<u>Issue Date</u>
Oppermann et al.	5,011,691	April 30, 1991
Hunziker	5,270,300	December 14, 1993
Oppermann et al.	5,324,819	June 28, 1994
Oppermann et al.	5,354,557	October 11, 1994
Wolfman et al.	5,399,677	March 21, 1995
Grinna et al.	5,411,941	May 2, 1995
Lee	5,686,425	November 11, 1997
Isner et al.	5,980,887	November 9, 1999
Goldberg et al.	6,013,624	Jan 11, 2000

Foreign Patent Publications

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Genetics Institute, Inc.	WO93/09229	May 13, 1993
Genetics Institute, Inc.	WO95/05846	March 2, 1995

Other Documents

Alini, et al., A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation, Dev. Biol., 176, pp. 124-133 (1996).

Battegay, Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects, J. Mol. Med., 73, pp. 333-346 (1995).

Bussolini, et al., Molecular mechanisms of blood vessel formation, Trends Biochem. Sci., 22, pp. 251-256 (1997).

Duneas, et al., Transforming growth factor - β 1: induction of bone morphogenetic protein genes expression during endochondral bone formation in the baboon, and synergistic interaction with osteogenic protein-1 (BMP-7), Growth Factors, 15, pp. 259-277 (1998).

Folkman, Angiogenesis: initiation and control, Ann. NY Acad. Sci., 401, pp. 212-227 (1982).

Folkman and Klagsbrun, Angiogenic factors, Science, 235, pp. 442-447 (1987).

Gerber, et al., VEGF couples hypertrophic cartilage remodelling, ossification, and angiogenesis during endochondral bone formation, Nat. Med., 5, pp. 623-628 (1999).

Glowacki, Angiogenesis in fracture repair, Clin. Orthop., 355, pp. S82-S89 (1998).

Hanada, et al., Stimulatory effects of basic Fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells, J. Bone and Mineral Res., 12, pp. 1606-1614 (1997).

Hayek, et al., An in vivo model for studying the angiogenic effects of basic fibroblast growth factor, Biochem. Biophys. Res. Commun., 147, pp. 876-880 (1987).

Isner, et al., Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization, J. Clin. Invest., 103, pp. 1231-1236 (1999).

Liem, et al., Dorsal differentiation of neural plate cells induced by BMP-mediated signals from epidermal ectoderm, Cell, 82, pp. 967-979 (1995).

Ripamonti, et al., Recombinant transforming growth factor β 1 induces endochondral bone in the baboon and synergized with recombinant OP-1 to initiate rapid bone formation, J. Bone and Mineral Res., 12, pp. 1584-1595 (1997).

Si, et al., Induction of new bone by ceramic bovine bone with recombinant human bone morphogenetic protein 2 and transforming growth factor, International J. Oral Maxillofacial Surgery, 27, pp. 310-314 (1998).

Yamashita, et al., Growth/differentiation factor-5 induces angiogenesis in vivo, Exp. Cell. Res., 235, pp. 218-226 (1997).

Yancopoulos, et al., Vasculogenesis, angiogenesis and growth factors: ephrins enter the fray at the border, Cell, 93, pp. 661-664 (1998).

Zagzag, Angiogenic growth factors in neural embryogenesis and neoplasia, Am. J. Pathol., 146, pp. 293-309 (1995).

Zimrin and Maciag, Progress towards a unifying hypothesis for angiogenesis, J. Clin. Invest., 97, p. 1359 (1996).

This Statement is submitted more than three months from the application filing date but before the mailing date of the first substantive Office Action. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.


The Commissioner, however, is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Karen Mangasarian (Reg. No. 43,772)
Agent for Applicants
c/o FISH AND NEAVE
1251 Avenue of the Americas
New York, New York 10020
Telephone: (212) 596-9000

I HEREBY CERTIFY THAT THIS
CORRESPONDENCE IS BEING
DEPOSITED WITH THE U.S.
POSTAL SERVICE AS FIRST
CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT
COMMISSIONER FOR
PATENTS
U.S. PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231 ON
July 28, 2001



For use of person signing